AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) Director Ecor1 Capital, Llc bought 138,093 shares of the stock in a transaction on Wednesday, November 18th. The shares were bought at an average cost of $46.54 per share, with a total value of $6,426,848.22. Following the purchase, the director owned 8,254,674 shares of the company’s stock, valued at $384,172,527.96. This trade represents a 1.70% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Ecor1 Capital, Llc also recently made the following trade(s):
- On Tuesday, November 17th, Ecor1 Capital, Llc purchased 152,367 shares of AnaptysBio stock. The shares were bought at an average price of $45.66 per share, with a total value of $6,957,077.22.
- On Monday, November 16th, Ecor1 Capital, Llc purchased 84,120 shares of AnaptysBio stock. The shares were bought at an average price of $45.66 per share, with a total value of $3,840,919.20.
AnaptysBio Trading Up 3.2%
Shares of AnaptysBio stock traded up $1.45 on Wednesday, reaching $47.06. The company had a trading volume of 566,852 shares, compared to its average volume of 658,208. The firm’s 50 day moving average price is $49.35 and its two-hundred day moving average price is $56.27. The firm has a market cap of $1.40 billion, a PE ratio of 9.49 and a beta of 0.70. AnaptysBio, Inc. has a 52-week low of $22.07 and a 52-week high of $72.36. The company has a debt-to-equity ratio of 0.17, a quick ratio of 8.40 and a current ratio of 8.40.
AnaptysBio (NASDAQ:ANAB – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The biotechnology company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.84) by $1.95. AnaptysBio had a net margin of 96.30% and a negative return on equity of 17.54%. The firm had revenue of $30.27 million during the quarter, compared to analysts’ expectations of $25.56 million. Sell-side analysts predict that AnaptysBio, Inc. will post -1.30 earnings per share for the current fiscal year.
Hedge Funds Weigh In On AnaptysBio
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in shares of AnaptysBio during the second quarter worth about $124,473,000. Affinity Asset Advisors LLC raised its holdings in AnaptysBio by 111.4% in the first quarter. Affinity Asset Advisors LLC now owns 940,000 shares of the biotechnology company’s stock valued at $52,132,000 after acquiring an additional 495,308 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in AnaptysBio by 45.6% in the third quarter. Goldman Sachs Group Inc. now owns 850,343 shares of the biotechnology company’s stock worth $42,738,000 after acquiring an additional 266,273 shares during the last quarter. Palo Alto Investors LP purchased a new position in AnaptysBio in the second quarter worth approximately $40,735,508. Finally, First Light Asset Management LLC grew its holdings in AnaptysBio by 2.9% during the 2nd quarter. First Light Asset Management LLC now owns 582,004 shares of the biotechnology company’s stock worth $39,285,000 after acquiring an additional 16,573 shares in the last quarter.
Analyst Upgrades and Downgrades
A number of research analysts have commented on the company. Wall Street Zen cut AnaptysBio from a “buy” rating to a “hold” rating in a research note on Sunday, October 4th. Scotiabank downgraded shares of AnaptysBio to a “hold” rating and set a $70.00 target price on the stock. in a research note on Tuesday, August 25th. TD Cowen reduced their target price on shares of AnaptysBio from $75.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday, August 25th. Wolfe Research reissued an “outperform” rating and issued a $78.00 price target on shares of AnaptysBio in a research report on Monday, August 31st. Finally, HC Wainwright restated a “buy” rating and issued a $95.00 price target on shares of AnaptysBio in a research note on Tuesday, September 22nd. Twelve analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $75.67.
Check Out Our Latest Research Report on ANAB
About AnaptysBio
AnaptysBio is a biotechnology company focused on developing antibody-based treatments for inflammatory and autoimmune diseases. Its research programs target immune pathways that may be involved in conditions with significant unmet medical needs. The company’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 pathway, and ANB032, an investigational antibody targeting BTLA. AnaptysBio has also developed imsidolimab, an antibody targeting the IL-36 receptor; global rights to that program were licensed to Vanda Pharmaceuticals.
Featured Articles
- Five stocks we like better than AnaptysBio
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.
